高级检索
当前位置: 首页 > 详情页

Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine.

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, Yunnan Province, China [2]Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA [3]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong Province, China [4]Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
出处:
ISSN:

关键词: Rotavirus SR69A-VP8*/S60-VP8* nanoparticle Rotavirus vaccine Rotavirus NSP4 Rotavirus VP8 Non-replicating rotavirus vaccine Norovirus

摘要:
Rotavirus causes severe diarrhea and dehydration in young children. Even with the implementation of the current live vaccines, rotavirus infections still cause significant mortality and morbidity, indicating a need for new rotavirus vaccines with improved efficacy. To this end, we have developed an SR69A-VP8*/S60-VP8* nanoparticle rotavirus vaccine candidate that will be delivered parenterally with Alum adjuvant. In this study, as parts of our further development of this nanoparticle vaccine, we evaluated 1) roles of rotavirus nonstructural protein 4 (NSP4) that is the rotavirus enterotoxin, a possible vaccine target, and an immune stimulator, and 2) effects of CpG adjuvant that is a toll-like receptor 9 (TLR9) ligand and agonist on the immune response and protection of our SR69A-VP8*/S60-VP8* nanoparticle vaccine. The resulted vaccine candidates were examined for their IgG responses in mice. In addition, the resulted mouse sera were assessed for i) blocking titers against interactions of rotavirus VP8* proteins with their glycan ligands, ii) neutralization titers against rotavirus replication in cell culture, and iii) passive protection against rotavirus challenge with diarrhea in suckling mice. Our data showed that the Alum adjuvant appeared to work better with the SR69A-VP8*/S60-VP8* nanoparticles than the CpG adjuvant, while an addition of the NSP4 antigen to the SR69A-VP8*/S60-VP8* vaccine may not help to further increase the immune response and protection of the resulted vaccine. Copyright © 2020 Elsevier Ltd. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 医学:研究与实验
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 医学:研究与实验
第一作者:
第一作者机构: [1]Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, Yunnan Province, China
共同第一作者:
通讯作者:
通讯机构: [2]Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA [4]Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA [*1]Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229-3039, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号